Sep 11,2023 TOP STORY

Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results

Nemaura Medical , a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized diabetes management and metabolic health programs, today announced it has recently completed a 100-patient study across 4 cohorts of 25 diabetic patients for sugarBEAT® and provided interim results. This study was designed to evaluate several factors, including the possibility of increasing the wear period to up to 24 hours, evaluating the possibility of auto-calibration, and different methods of application of the device to the skin. The study was conducted in the Middle East on 100 adult patients aged 18 to 75 comprising 20 persons with Type 1 diabetes and 80 persons with Type 2 diabetes. The Company reports interim data from a first cohort comprising 25 patients, on a single day sensor wear. The results indicate that a 24-hour sensor wear period using a single sensor is possible, which is expected to allow users to monitor their glucose fluctuations overnight.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 12,2023 TOP STORY

Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France

DexCom, Inc. today announced the availability of its Dexcom ONE real-time CGM sensor via reimbursement, in France. Specifically, access is now secured to the Dexcom ONE sensor for all patients with type 1 and type 2 diabetes, two years and older, who are undergoing intensive insulin therapy (by external pump or >3 injections per day). “We believe this is truly exciting news for people living with diabetes in France,” said Gérald Zammit, Country Director of Dexcom France. "Access to Dexcom real-time CGM sensors is now available to those who live with diabetes, who aren’t necessarily seen as ‘high risk’, but who can still greatly benefit from it. The launch of Dexcom ONE in France will help to make real-time CGM accessible to as many patients as possible.”

PRODUCT

#reimbursement

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 12,2023

Nemaura Medical Announces Participation at HLTH 2023, Las Vegas

Nemaura Medical, a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting diabetes management and personalized lifestyle coaching programs, today announced it will be participating at the HLTH 2023 conference, in Las Vegas, in October.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 13,2023

Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program

Nemaura Medical, a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced interim results from its metabolic health program. The primary objective of the study was to establish whether a metabolic program with a daily wear CGM worn twice a month resulted in greater engagement levels and sustainable weight reduction, and how this compared to other programs. The multi-centered study was run in collaboration with the UK’s National Health Service. Known as Miboko (Mind, Body, Konnect), the program is the first to integrate a daily-wear and non-invasive glucose sensor with the Company’s bespoke app, educational content and AI driven analytics platform. Qualitative feedback from users demonstrated substantially increased levels of understanding and empowerment on their weight loss goals, correlating to long-term behavioural changes that are pivotal to sustained weight loss. After 20 weeks of use, the program had a retention rate of 32.5%. When active participants were asked whether they would continue with the program, 64% of respondents stated they were likely or very likely to continue to use the program. The Company plans to publish more detailed results in due course.

CLINICAL STUDY

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 01,2017

Evaluation of a Digital Behavioral Counseling Program for Reducing Risk Factors for Chronic Disease in a Workforce

The aim of the study from Omada Health is to evaluate a digitally delivered, intensive behavioral counseling program for a workforce at risk for obesity-related chronic disease. Employees were offered a digital health program modeled after the diabetes prevention program (DPP). Annual workforce health assessments were used to examine changes in chronic disease risk factors between participants (n = 634) relative to a matched comparison group (n = 1268). Overall, employees were gaining an average of 3.5 pounds annually before program inception. Program engagement was positive; 83% completed the majority of the curriculum and 31% lost at least 5% of their starting weight. Compared with non-participating peers, participants demonstrated reduced weight, improved fasting blood glucose, and improved nutritional intake after a year.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 17,2023

A Tsunami of New GLP-1s May Hit the Market — What Does That Mean for Costs?

GLP-1s are a type of incretin mimetic, medications that affect gut hormones and cause weight loss. Beyond their effectiveness, price point is a widespread concern for stakeholders throughout the healthcare industry, as well as for chronic disease patients who might hope to use them. Ozempic®, for example, costs an estimated $10,000 a year per person, placing significant financial strain on payers as demand grows. While cost concerns are not seem to slow down, pharmaceutical companies are scrambling to get more weight loss drugs approved by the FDA and put more GLP-1s on the market. Will more supply to meet growing demand for these medications bring prices down? And just how many GLP-1s are there? This article from Omada Health discusses the impact of GLP-1 prescriptions on healthcare costs, and Omada's response to the increasing demand for GLP-1s.

View Analyst & Ambassador Comments
Go to original news
Aug 31,2023

Omada Health Presents at HLTH Conference

Omada Health shared their upcoming participation as a proud sponsor at this year's HLTH Conference, taking place from October 8-11th. Here's what you can expect from Omada Health. The CEO of Omada Health, Sean Duffy, along with Chrissy Far-Health Tech Investor, OMERS Venture, Stephen Gillet-CEO, Verily and Julia Cheek-Founder and CEO, Everly Health, take the “Moon” stage on Monday, October 9th, from 1:20 - 2:00 PM PT to discuss the future of virtual care and what it means to be a first mover in digital health.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 05,2023

Non-Invasive Blood Glucose Monitoring System Market to Hit USD 202.73 Million by 2032

The global non-invasive blood glucose monitoring system market was valued at USD 21.76 million in 2022 and is expected to hit around USD 202.73 million by 2032, growing at a healthy CAGR of 25% from 2023 to 2032, according to the study publisher. The convenience and ease of use provided by non-invasive blood glucose monitoring systems are stated as the key drivers of market growth.

View Analyst & Ambassador Comments
Go to original news
Aug 28,2023 TOP STORY

Insulet Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System in Germany

Insulet Corporation today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D) in its third market, Germany. The company launched Omnipod 5 in the U.S. in August 2022, then began its launch in the UK in June of this year. Omnipod 5 is the first CE marked tubeless automated insulin delivery (also known as hybrid closed loop) system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System. The system includes the tubeless Pod enhanced with SmartAdjust technology and a handheld Controller integrated with the SmartBolus Calculator. The system is interoperable with Dexcom G6 for automated insulin delivery to help protect against high and low glucose levels.

PRODUCT

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 30,2023

Hygieia welcomes Heineman as Vice President of Business Development

A provider of digital therapeutics for insulin management, Hygieia, has announced the hire of Zoe Heineman as Vice President of Business Development. Heineman brings over 30 years of expertise in strategic leadership, operations, and business development in the biopharmaceutical and medical device industries. She is an internationally known member of the diabetes community with a track record of opening new markets for diabetes technology.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES